- In January 2022, 4D Molecular Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted the fast-track designation to 4D-125 which is used to treat X-linked retinitis pigmentosa. 4D-125 is a targeted and evolved R100-based product candidate meant to deliver a functional copy of the RPGR gene to photoreceptors in the retina. It was invented at 4DMT for efficient intravitreal delivery
